Renal cell carcinoma advanced

Patients with advanced renal cell carcinoma... [Pg.450]

Ratain, M., Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase 11 randomized discontinuation trial (RDT), Proc. Am. Soc. Clin. Oncol., 22, 381, Abstr. 4501, 2004. [Pg.458]

Everolimus (40 Afinitor Novartis, 2009), a rapamycin analog, is the 42-0-(2-hydroxyethyl) derivative of sirolimus (34), and is marketed as an immunosuppressant by Novartis under the tradename Afinitor for use in advanced renal cell carcinoma.In March 2009, the FDA approved everolimus (40) for use against advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib. The drug works similarly to sirolimus as an inhibitor of mTOR (mammalian target of rapamycin), a serine-threonine kinase, downstream of the PI3K/AKT pathway. Everolimus (40) binds to an intracellular protein, EKBP-12, resulting in an inhibitory... [Pg.44]

Gore ME. (2007) Temsirolimus in the treatment of advanced renal cell carcinoma Ann Oncol 18(Suppl 9) ix87-ix88. [Pg.142]

Sorafenib is a kinase inhibitor with both antiproliferative and anti-angiogenic activity. Approved for the treatment of advanced renal cell carcinoma and for the treatment of patients with hepatocellular carcinoma. Peak plasma levels of sorafenib are generally observed 3 hours after oral administration. The... [Pg.459]

Yagoda A, Abi-Bached B, Petrylak D. Chemotherapy for advanced renal cell carcinoma 1983-1993. Semin Oncol 1995 22 42-60. [Pg.727]

Keisner SV et al (2011) Pazopanib the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs 71 443 154... [Pg.242]

Sorafenib (Nexavar) A Multikinase Inhibitor for Advanced Renal Cell Carcinoma and Unresectable Hepatocellular Carcinoma... [Pg.73]

Sorafenib (l)11 is a multikinase inhibitor marketed by Bayer and Onyx. Sorafenib blocks tyrosine kinases as well as serine/threonine kinases. Its story began in 1994 when Bayer and Onyx entered a collaboration to discover novel Raf/MEK/ERK inhibitors. They first discovered a very mildly active compound 8 (/C50 17 pM) against Rafl kinase in 1995 from screening a collection of 200,000 compounds. The optimization of its potency and its ADMET profile using medicinal chemistry and combinatorial chemistry methods led to the identification of sorafenib (1) in 1999 as a preclinical development candidate. Multiple phase I studies started in 2000, when sorafenib tosylate (19) was evaluated in patents with advanced solid tumors of different types. In December 2005, Sorafenib tosylate (19) received U.S. FDA approval for the treatment of advanced renal cell carcinoma (RCC). Two years later, it was approved for the treatment of unresectable hepatocellular carcinoma (HCC). [Pg.75]

In summary, sunitinib maleate (1) is a multitargeted receptor tyrosine kinase inhibitor with potent anti-angiogenic and antitumor activity. It is approved for the treatment of advanced renal cell carcinoma and gastrointestinal stromal tumors, and is currently undergoing clinical trials for a number of additional malignancies. The discovery synthesis of 1 along with its process development approaches were described in this chapter. [Pg.97]

In summary, pazopanib (1) is an orally administered, new and potent VEGFR inhibitor and is the approved treatment for advance renal cell carcinoma (RCC), the most common type of kidney cancer. More than 2,000 patients have been treated to date in clinical trials, with potent antitumor activity for RCC. [Pg.120]

Luemmen G, Sperling H, Luboldt H, Otto T, Ruebben H (1998) Phase II trial of titanocene dichloride in advanced renal-cell carcinoma. Cancer Chemother Pharmacol 42 415—417... [Pg.48]

Motzer RJ, Rakhit A, Schwartz LH, Olencki T, Malone TM, Sandstrom K et al. Phase 1 trial of subcutaneous human interleukin-12 in patients with advanced renal cell carcinoma. Clin Cancer Res 1998 4 1183-91. [Pg.500]

Law TM, Motzer RJ, Mazumdar M, Sell KW, Walther PJ, O Connell M, Khan A, Vlamis V, Vogelzang NJ, Bajorin DF. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 1995 76(5) 824-32. [Pg.66]

Davis SD, Berkmen YM, Wang JC. Interleukin-2 therapy for advanced renal cell carcinoma radiographic evaluation of response and complications. Radiology 1990 177(1) 127-31. [Pg.67]

Abdi EA, Nguyen GK, Ludwig RN, Dickout WJ. Pulmonary sarcoidosis following interferon therapy for advanced renal cell carcinoma. Cancer 1987 59(5) 896-900. [Pg.1838]

Of 49 patients with advanced renal cell carcinoma treated with subcutaneous interleukin-4 (4 micrograms/kg/ day for 28 days followed by a 7-day rest), nine had 13 episodes of grade 4 toxicity (3). Severe unexpected toxic effects included three cases of Bell s palsy and one episode of severe hypoglycemia in a previously well-con-trolled patient with diabetes mellitus. [Pg.1846]

Whitehead RP, Lew D, Flanigan RC, Weiss GR, Roy V, Glode ML, Dakhil SR, Crawford ED. Phase II trial of recombinant human interleukin-4 in patients with advanced renal cell carcinoma a Southwest Oncology Group study. J Immunother 2002 25(4) 352-8. [Pg.1846]

Suramin was not effective in one phase II study in advanced renal cell carcinoma, in which it was given in a fixed dose plus hydrocortisone to 22 patients (19 men, three women, aged 30-74 years) (11). Three patients had grade 4 toxicity (hypersensitivity, urethral obstruction, hypotension, and neutropenic sepsis). Eleven developed grade 3 toxicity, mainly abdominal pain, anemia, diarrhea, erythema, dyspnea, fatigue, and fever. [Pg.3251]

Schroder LE, Lew D, Flanigan RC, Eisenberger MA, Seay TE, Hammond N, Needles BM, Crawford ED. Phase 11 evaluation of suramin in advanced renal cell carcinoma. A Southwest Oncology Group study. Urol Oncol 2001 6(4) 145-8. [Pg.3254]

Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 2003 98 962-969. [Pg.565]

Goodman VL, Rock EP, Dagher R, et al. Approval summary Sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res. 2007 13(5) 1367-1373. [Pg.327]

Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 125-134... [Pg.210]

Indications Advanced renal cell carcinoma Category Tyrosine kinase inhibitor Half-life 25-48 hours... [Pg.530]

Boorjian SA, Milowsky MI, Kaplan J, et al. Phase 1/2 clinical trial of interferon a2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma. J Immunother 2007 30 655-662. [Pg.398]

Miller, W.H., Jr, Reyno, L.M., Loewen, G.R., Huan, S., Winquist, E., Moore, M., Cato, A., 3rd, Jaunakais, D., Truglia, J.A., Matthews, S., Dancey, J. and Eisenhauer, E. (2000) A phase I—II study of 9-cis retinoic add and interferon-a2b in patients with advanced renal-cell carcinoma an NCIC Clinical Trials Group study. Annals of Oncology, 11, 1387-1389. [Pg.402]

Motzer, R.J., Murphy, B.A., Bacik, J., Schwartz, L.H., Nanus, D.M., Mariani, T., Loehrer, P., Wilding, G., Fairclough, D.L., Celia, D. and Mazumdar, M. (2000) Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. Journal of Clinical Oncology, 18, 2972-2980. [Pg.402]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...